Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by SundayMovieson Dec 09, 2022 10:00am
152 Views
Post# 35161447

RE:RE:Good results but...

RE:RE:Good results but...Davepark5

Look at the market cap. KTRA is a very small market cap.

For PII biotech with fast track, market is saying 100 millions USD$ is what it is worth. 
This is undervalue and all analysts covering this stock is already saying but market sentiment is very negative as the market is pricing in a recession / end of rate hikes.

The general should improve (bullish view), if so SP could shoot higher as specaltion of successful bracelet trial become louder. 

A PIII biotech in oncology is worth at least 500 millions... 
So ONCY has 33 millions in cash, market is saying that ONCY tech is worth only 66 millions
Wow, this is very cheap valuation. A bargain vs. the potential. 

<< Previous
Bullboard Posts
Next >>